Trial Profile
Post-Marketing Surveillance of the Safety, Tolerability and Efficacy of Ezetimibe Among Filipino Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; HMG-CoA reductase inhibitors
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Organon; Schering-Plough
- 15 Jul 2009 Actual patient number (4105) added as reported by ClinicalTrials.gov.
- 29 Sep 2008 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 29 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.